Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shay Yeganeh, Mahdi Assaly, Anna Gourevitch, Revital Saban, Moshe E Gatt, Pia Raanani, Iuliana Vaxman

Blood (2022) 140 (Supplement 1): 11981–11982.

https://doi.org/10.1182/blood-2022-163009

Published: 2022

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment

Moshe E. Gatt, MD, Izhar Hardan, MD, Evgene Chubar, MD, Celia Surio, Tamar Tadmor, MD, Olga Shvez, Paulina Patachenco, Najib Dali, MD, Shay Yeganeh, MD, Irit Avivi, MD

Blood (2012) 120 (21): 1860.

https://doi.org/10.1182/blood.V120.21.1860.1860

Published: 2012

NARROW

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment

Email alerts

ASH Publications

American Society of Hematology

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Outcomes of AL Amyloidosis Patients Treated with Novel Agents: A Collaborative Retrospective Multicenter Assessment

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only